Cardiovascular Drugs and Therapy

, Volume 27, Issue 2, pp 171–179 | Cite as

RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials

  • Thomas G. von Lueder
  • Henry Krum
Review Article


Hypertension, coronary artery disease and heart failure affect over half of the adult population in most Western societies, and are prime causes of CV morbidity and mortality. With the ever-increasing worldwide prevalence of CV disease due to ageing and the “diabetes” pandemic, guideline groups have recognized the importance of achieving cardioprotection in affected individuals as well as in those at risk for future CV events. The renin-angiotensin-aldosterone system (RAAS) is the most important system controlling blood pressure (BP), cardiovascular and renal function in man. As our understanding of the crucial role of RAAS in the pathogenesis of most, if not all, CV disease has expanded over the past decades, so has the development of drugs targeting its individual components. Angiotensin-converting enzyme inhibitors (ACEi), Ang-II receptor blockers (ARB), and mineralcorticoid receptor antagonists (MRA) have been evaluated in large clinical trials for their potential to mediate cardioprotection, singly or in combination. Direct renin inhibitors are currently under scrutiny, as well as novel dual-acting RAAS-blocking agents. Herein, we review the evidence generated from large-scale clinical trials of cardioprotection achieved through RAAS-blockade.


RAAS ACE-inhibitor ARB Cardioprotection Hypertension Heart failure 


  1. 1.
    Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1(2):45–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Krum H, von Lueder T. Advances in Heart Failure Management. Future Medicine Ltd; 2012.Google Scholar
  3. 3.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRefGoogle Scholar
  4. 4.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRefGoogle Scholar
  5. 5.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–91.CrossRefGoogle Scholar
  6. 6.
    Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown Jr EJ, Cuddy TE. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.PubMedCrossRefGoogle Scholar
  8. 8.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342(8875):821–8.Google Scholar
  9. 9.
    Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332(2):80–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation. 1999;100(23):2312–8.Google Scholar
  11. 11.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.PubMedCrossRefGoogle Scholar
  12. 12.
    The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.Google Scholar
  13. 13.
    Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.PubMedCrossRefGoogle Scholar
  16. 16.
    Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.PubMedCrossRefGoogle Scholar
  20. 20.
    Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 2003;362(9386):759–66.PubMedCrossRefGoogle Scholar
  22. 22.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362(9386):767–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362(9386):772–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Leier CV, Young JB, Levine TB, Pina I, Armstrong PW, Fowler MB, et al. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination. Congest Heart Fail. 2001;7(6):297–308.PubMedCrossRefGoogle Scholar
  26. 26.
    Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.PubMedCrossRefGoogle Scholar
  27. 27.
    Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372(9644):1174–83.PubMedCrossRefGoogle Scholar
  28. 28.
    McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1477–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Haller H, Ito S, Izzo Jr JL, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–17.PubMedCrossRefGoogle Scholar
  30. 30.
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.PubMedCrossRefGoogle Scholar
  31. 31.
    Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012.Google Scholar
  32. 32.
    McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100(10):1056–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, et al. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008;29(20):2489–96.PubMedCrossRefGoogle Scholar
  34. 34.
    Pitt B, Stier Jr CT, Rajagopalan S. Mineralocorticoid receptor blockade: New insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4(3):164–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.PubMedCrossRefGoogle Scholar
  36. 36.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). EurJHeart Fail. 2010;12(6):617–22.CrossRefGoogle Scholar
  38. 38.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.PubMedCrossRefGoogle Scholar
  39. 39.
    Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, et al. Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: A double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur J Heart Fail. 2010;12(8):874–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162(6):966–72. e10.PubMedCrossRefGoogle Scholar
  43. 43.
    SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study). http://clinicaltrialsgov/ct2/show/NCT00604006?term=SCREEN-HF&rank=3. 2012:accessed Oct 17, 2012.
  44. 44.
    Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13(1):107–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Bohm M, Gimpelewicz C, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011;13(1):100–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663–71.PubMedCrossRefGoogle Scholar
  47. 47.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012;13(3):387–93.PubMedCrossRefGoogle Scholar
  48. 48.
    McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14(4):341–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: New insights from continuous monitoring devices. Curr Heart Fail Rep. 2009;6(4):287–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26(6 Pt 2):1160–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Alehagen S, Wijma K, Wijma B. Can women’s cognitive appraisals be registered throughout childbirth? Gynecol Obstet Invest. 2000;49(1):31–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Munagala VK, Burnett Jr JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29(12):707–69.PubMedCrossRefGoogle Scholar
  54. 54.
    Johansson P, Brostrom A, Dahlstrom U, Alehagen U. Global perceived health and ten-year cardiovascular mortality in elderly primary care patients with possible heart failure. Eur J Heart Fail. 2008;10(10):1040–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–11.PubMedCrossRefGoogle Scholar
  56. 56.
    Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol. 2011;57(4):495–504.PubMedCrossRefGoogle Scholar
  59. 59.
    Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–14.PubMedCrossRefGoogle Scholar
  60. 60.
    Von Lueder T, Wang B, Kompa A, Huang L, Webb R, Jordan P, et al. ARNi, combined neprilysin and angiotensin receptor inhibition augments anti-fibrotic and anti-hypertrophic effects in vitro. Eur Heart J. 2012;33:P5834.Google Scholar
  61. 61.
    Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.PubMedCrossRefGoogle Scholar
  62. 62.
    US National Library of Medicine. Clinical [online]. http://clinicaltrialsgov/ct2/show/NCT01035255?term=paradigm-HF&rank=1 2012.
  63. 63.
    Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–95.PubMedCrossRefGoogle Scholar
  64. 64.
    Cleland JG, Clark AL. Heart failure–does it matter whether LVEF is reduced? Lancet. 2012;380(9851):1363–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox. Circulation. 2006;114(8):838–54.PubMedCrossRefGoogle Scholar
  66. 66.
    Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: Meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.PubMedCrossRefGoogle Scholar
  67. 67.
    van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.PubMedCrossRefGoogle Scholar
  68. 68.
    Ruschitzka F, Taddei S. Angiotensin-converting enzyme inhibitors: First-line agents in cardiovascular protection? Eur Heart J. 2012;33(16):1996–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Watanabe M, Krum H. Eplerenone for the treatment of cardiovascular disorders. Expert Rev Cardiovasc Ther. 2012;10(7):831–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of Epidemiology and Preventive MedicineMonash Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Alfred HospitalMelbourneAustralia
  2. 2.Department of Cardiology BOslo University Hospital UllevålOsloNorway

Personalised recommendations